Douglas Lane & Associates’s Roivant Sciences ROIV Stock Holding History

Douglas Lane & Associates’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$279K	Hold	7,886	–	–	﹤0.01%	229
2026 Q1	$218K	Buy	+7,886	New	+$203K	﹤0.01%	230

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Douglas Lane & Associates's ROIV Position: Q2 2026 in Review

Douglas Lane & Associates held its Roivant Sciences (ROIV) position steady in Q2 2026 at 7,886 shares worth $279K. The position accounts for ﹤0.01% of the portfolio, ranked #229.

Douglas Lane & Associates first reported a position in ROIV in Q1 2026 and has held it in 2 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Douglas Lane & Associates held 7,886 shares of Roivant Sciences worth $279K as of Q2 2026.
Douglas Lane & Associates left its Roivant Sciences share count unchanged in Q2 2026.
Roivant Sciences made up ﹤0.01% of Douglas Lane & Associates's portfolio in Q2 2026, its #229 holding.
Douglas Lane & Associates first reported a position in Roivant Sciences in Q1 2026 and has held it in 2 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Douglas Lane & Associates's 13F filing for Q2 2026, filed 14 Jul 2026.